Bright Minds Biosciences (DRUG) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bright Minds Biosciences (DRUG) has outperformed Monopar Therapeutics (MNPR) over the past year, losing 5.8% versus a loss of 14.8%. Over five years, MNPR leads with a +242.1% price change compared with +40.0% for DRUG. Monopar Therapeutics is the larger company by market cap ($549.5 million vs $540.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | MNPR |
|---|---|---|
| Share price | $54.78 | $81.87 |
| Market cap | $540.30M | $549.53M |
| 1-day change | +5.34% | -2.51% |
| YTD return | -33.37% | +28.61% |
| 1-year return | -5.80% | -14.80% |
| 5-year return | +39.97% | +242.08% |
| EPS (TTM) | $-2.05 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $124.82 |
| 52-week low | $47.23 | $50.07 |
| Distance from 52-week high | -55.74% | -34.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +177.44% | +58.69% |
| Average volume | 159.01K | 213.15K |
| Shares outstanding | 9.86M | 6.71M |
| Employees | 26 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
DRUG vs MNPR FAQ
Which is bigger, Bright Minds Biosciences or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $549.53M compared with $540.30M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, DRUG or MNPR?
DRUG returned -5.80% over the past 12 months, compared with -14.80% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.